Inve US ▾

West Pharmaceutical Services (WST) earnings

WEST PHARMACEUTICAL SERVICES INC· Health Care

Results to
Jun 2026
Latest analysed call
Jun 2026 (Q2 FY26)
Balance sheet to
Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

West Pharmaceutical Services earnings: last reported Thu, 23 Jul 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue872 $ million+13.8% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin20.5 %+0.5 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit154 $ million+16.8% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Guidance

What management said, and what became of it

10 of 12 judged targets kept · 14 open · verdicts reflect calls analysed to Jun 2026.

WEST PHARMACEUTICAL SERVICES INC management guidance track record on Inve: 26 targets tracked across analysed earnings calls (10 achieved, 2 missed, 14 open).

TargetOriginal wordingSaidLatest callVerdict
Quarterly adjusted diluted EPS$2.05 to $2.12Mar 2026Jun 2026:adjusted EPS of $2.37, was up 29% as compared to prior year.
Call transcript, Jun 2026 · no direct link		Achieved
Full-year adjusted diluted EPS$7.85 to $8.20Dec 2025Jun 2026:This results in adjusted earnings per share to be between $8.85 to $9.05 for the year, up 21% to 24% year-on-year.
Call transcript, Jun 2026 · no direct link		Revised Up
Annex 1 revenue growth contributionabout 200 basis pointsDec 2025Jun 2026:We saw continued growth in Annex 1 related projects in the quarter, and we expect this mix shift to deliver our target of 200 basis points of revenue growth in 2026.
Call transcript, Jun 2026 · no direct link		On Track

Source: Inve Guidance Tracker for WEST PHARMACEUTICAL SERVICES INC · to Jun 2026

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of WEST PHARMACEUTICAL SERVICES INC's 26 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 23 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. US Pro opens 100 a month: first month free, no card.
See the full record

Price

$392.15 −0.48% · −$1.88

Last close Oct 23, 2026 · US · USD · Source: Inve

Performance +41.6% 1Y

$250$300$350$400Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Mar 2026 (Q1 FY26) — 23 Apr 2026Jun 2026 (Q2 FY26) — 23 Jul 2026

1Y: $277 on 22 Oct 2025 → $392.15. High $394.03 (22 Oct 2026), low $230.95 (3 Feb 2026).

Previous close
$394.03
52-week range
$230.95 – $394.03
One year
+27.63%

Overview

Symbol
WST
Exchange
US
Currency
USD

Your own record

Start an Inve Case for WEST PHARMACEUTICAL SERVICES INC

Free account. Everything above stays public.

Write why you follow WEST PHARMACEUTICAL SERVICES INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other US companies filed under W

All 99 companies under W

US companies A–Z · Earnings calls · US earnings-call directory · US sector analysis · What management promised, and delivered